The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Direct medical costs and their predictors in patients with rheumatoid arthritis: A three‐year study of 7,527 patients
Abstract
Objective: To estimate total direct medical costs in persons with rheumatoid arthritis (RA) and to characterize predictors of these costs. Methods: Patients (n = 7,527) participating in a longitudinal study of outcome in RA completed 25,050 semiannual questionnaires from January 1999 through December 2001. From these we determined direct medical care costs converted to 2001 US dollars using the consumer price index. We used generalized estimating equations to examine potential predictors of the costs. Monte Carlo simulations and sensitivity analyses were performed to evaluate the varying prevalence and cost of biologic therapy. Results: The mean total annual direct medical care cost in 2001 for a patient with RA was $9,519. Drug costs were $6,324 (66% of the total), while hospitalization costs were only $1,573 (17%). Approximately 25% of patients received biologic therapy. The mean total annual direct cost for patients receiving biologic agents was $19,016 per year, while the cost for those not receiving biologic therapy was $6,164. RA patients who were in the worst quartile of functional status, as measured by the Health Assessment Questionnaire, experienced direct medical costs for the subsequent year that were $5,022 more than the costs incurred by those in the best quartile. Physical status as determined by the Short Form 36 physical component scale had a similar large effect on RA costs, as did comorbidity. Medical insurance type played a more limited role. However, those without insurance had substantially lower service utilization and costs, and health maintenance organization patients had lower drug costs and total medical costs. Increased years of education, increased income, and majority ethnic status were all associated with increased drug costs but not hospitalization costs. Costs in all categories decreased after age 65 years. Conclusion: Estimates of direct medical costs for patients with RA are substantially higher than cost estimates before the biologic therapy era, and costs are now driven predominantly by the cost of drugs, primarily biologic agents. RA patients with poor function continue to incur substantially higher costs, as do those with comorbid conditions, and sociodemographic characteristics also play an important role in determination of costs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1992) · PubMed · Cited by 33,716
The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection
Ware, J. E., & Sherbourne, C. D. (1992) · Medical Care · doi:10.1097/00005650-199206000-00002 · Cited by 30,033
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
McHorney, C. A., Ware, J. E., Rachel Lu, J. F., & Sherbourne, C. D. (1994) · Medical Care · doi:10.1097/00005650-199401000-00004 · Cited by 4,458
Measurement of patient outcome in arthritis
Fries, J. F., Spitz, P., Kraines, R. G., & Holman, H. R. (1980) · Arthritis & Rheumatism · doi:10.1002/art.1780230202 · Cited by 4,382
The estimation of a preference-based measure of health from the SF-36
Brazier, J., Roberts, J., & Deverill, M. (2002) · Journal of Health Economics · doi:10.1016/s0167-6296(01)00130-8 · Cited by 3,026
American college of rheumatology preliminary definition of improvement in rheumatoid arthritis
Felson, D. T., Anderson, J. J., Boers, M., Bombardier, C., Furst, D., Goldsmith, C., Katz, L. M., Lightfoot, R., Paulus, H., Strand, V., et al. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380602 · Cited by 2,829
Self-citationClarify: Software for Interpreting and Presenting Statistical Results
Tomz, M., Wittenberg, J., & King, G. (2003) · Journal of Statistical Software · doi:10.18637/jss.v008.i01 · Cited by 1,432
The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales.
Fries, J. F., Spitz, P. W., & Young, D. Y. (1982) · PubMed · Cited by 1,318
Russo, J., Trujillo, C. A., Wingerson, D., Decker, K., Ries, R., Wetzler, H., & Roy-Byrne, P. (1998) · Medical Care · doi:10.1097/00005650-199805000-00015 · Cited by 1,308
Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study
Choi, H. K., Hernán, M. A., Seeger, J. D., Robins, J. M., & Wolfe, F. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08213-2 · Cited by 1,127
Self-citationThe Work Limitations Questionnaire
Lerner, D., Amick, B. C., Rogers, W. H., Malspeis, S., Bungay, K., & Cynn, D. (2001) · Medical Care · doi:10.1097/00005650-200101000-00009 · Cited by 971
THE EPIDEMIOLOGY OF RHEUMATOID ARTHRITIS
Gabriel, S. E. (2001) · Rheumatic Disease Clinics of North America · doi:10.1016/s0889-857x(05)70201-5 · Cited by 782
The prevalence and meaning of fatigue in rheumatic disease.
Wolfe, F., Hawley, D. J., & Wilson, K. (1996) · PubMed · Cited by 641
Self-citationThe arthritis impact measurement scales. further investigations of a health status measure
Meenan, R. F., Gertman, P. M., Mason, J. H., & Dunaif, R. (1982) · Arthritis & Rheumatism · doi:10.1002/art.1780250903 · Cited by 383
A self‐administered rheumatoid arthritis disease activity index (RADAI) for epidemiologic research
Stucki, G., Liang, M. H., Stucki, S., Brühlmann, P., & Michel, B. A. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380612 · Cited by 301
Wolfe, F., & Zwillich, S. H. (1998) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199806)41:6<1072::aid-art14>3.0.co;2-g · Cited by 291
Self-citationYelin, E., & Wanke, L. A. (1999) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199906)42:6<1209::aid-anr18>3.0.co;2-m · Cited by 238
The Work Limitations Questionnaire's validity and reliability among patients with osteoarthritis
Lerner, D., Reed, J. I., Massarotti, E., Wester, L. M., & Burke, T. A. (2002) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(01)00424-3 · Cited by 226
Reliability and validity of the EuroQol in patients with osteoarthritis of the knee
Fransen, M., & Edmonds, J. (1999) · Rheumatology · doi:10.1093/rheumatology/38.9.807 · Cited by 215
The costs of rheumatoid arthritis: an international long-term view
Pugner, K. M., Scott, D. I., Holmes, J. W., & Hieke, K. (2000) · Seminars in Arthritis and Rheumatism · doi:10.1016/s0049-0172(00)80017-7 · Cited by 211
Direct medical costs unique to people with arthritis.
Gabriel, S. E., Crowson, C. S., Campion, M. E., & O’Fallon, W. M. (1997) · PubMed · Cited by 200
Lanes, S. F., Lanza, L. L., Radensky, P. W., Yood, R. A., Meenan, R. F., Walker, A. M., & Dreyer, N. A. (1997) · Arthritis & Rheumatism · doi:10.1002/art.1780400816 · Cited by 173
THE COST OF RHEUMATOID ARTHRITIS
MCINTOSH, E. (1996) · Rheumatology · doi:10.1093/rheumatology/35.8.781 · Cited by 171
Economic consequences of the progression of rheumatoid arthritis in Sweden
Kobelt, G., Eberhardt, K., J�nsson, L., & J�nsson, B. (1999) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199902)42:2<347::aid-anr18>3.0.co;2-p · Cited by 169
The AIMS approach to health status measurement: conceptual background and measurement properties.
Meenan, R. F. (1982) · PubMed · Cited by 161
Fransen, J., Langenegger, T., Michel, B. A., & Stucki, G. (2000) · Rheumatology · doi:10.1093/rheumatology/39.3.321 · Cited by 158
Coronary artery disease and rheumatoid arthritis
Goodson, N. J. (2002) · Current Opinion in Rheumatology · doi:10.1097/00002281-200203000-00007 · Cited by 152
The costs of rheumatoid arthritis. a patient‐oriented study of chronic disease costs
Meenan, R. F., Yelin, E. H., Henke, C. J., et al. (1978) · Arthritis & Rheumatism · doi:10.1002/art.1780210714 · Cited by 136
Kobelt, G., Jönsson, L., Lindgren, P., Young, A., & Eberhardt, K. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10471 · Cited by 129
Clarke, A. E., Zowall, H., Levinton, C. M., Assimakopoulos, H., Sibley, J. T., Haga, M., Shiroky, J. B., Neville, C., Lubeck, D. P., Grover, S. A., et al. (1997) · PubMed · Cited by 126
The costs of rheumatoid arthritis: absolute, incremental, and marginal estimates.
Yelin, E. (1996) · PubMed · Cited by 112
Direct cost of rheumatoid arthritis during the first six years: a cost- of-illness study
van Jaarsveld, C. H. M., Jacobs, J. W. G., Schrijvers, G., Heurkens, A. H. M., Haanen, H. C. M., & Bijlsma, J. W. J. (1998) · Lara D. Veeken · doi:10.1093/rheumatology/37.8.837 · Cited by 90
Wolfe, F., Flowers, N., Burke, T. A., Arguelles, L., & Pettitt, D. (2002) · PubMed · Cited by 73
Self-citationFunctional Improvement and Costs of Hip and Knee Arthroplasty in Destructive Rheumatoid Arthritis
Jönsson, B., & Larsson, S. (1991) · Scandinavian Journal of Rheumatology · doi:10.3109/03009749109096811 · Cited by 55
A Review of the Direct Costs of Rheumatoid Arthritis
Lubeck, D. P. (2001) · PharmacoEconomics · doi:10.2165/00019053-200119080-00003 · Cited by 44
Warrington (2001) · Pure Amsterdam UMC · doi:10.1002/1529-0131(200101)44:1 · Cited by 2
Komuro (2001) · doi:10.1002/1529-0131(200112)44:12
Cited by
Charlson, M. E., Charlson, R. E., Peterson, J. C., Marinopoulos, S. S., Briggs, W. M., & Hollenberg, J. P. (2008) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2008.01.006 · Cited by 894
Anderson, J., Caplan, L., Yazdany, J., Robbins, M. L., Neogi, T., Michaud, K., Saag, K. G., O'dell, J. R., & Kazi, S. (2012) · Arthritis Care & Research · doi:10.1002/acr.21649 · Cited by 748
Self-citationWolfe, F., & Michaud, K. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22864 · Cited by 534
Self-citationRose, M., Bjorner, J. B., Becker, J., Fries, J. F., & Ware, J. E. (2008) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2006.06.025 · Cited by 503
Wolfe, F., Caplan, L., & Michaud, K. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21568 · Cited by 480
Self-citation
Metadata
- Authors
- Michaud, K., Messer, J., Choi, H. K., & Wolfe, F.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2003-10
- Volume
- 48
- Issue
- 10
- Pages
- 2750-2762
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W1556890549
- Cited by
- 271
- References
- 38
- FWCI
- 8.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.